(VIANEWS) – Aurora Cannabis (NYSE: ACB) witnessed its stock price plummet by 12.76% at 10:04 EST on Monday after two consecutive sessions of gains, following this shift across broader market as the NYSE dipped 0.56% to EUR18,112.04. Aurora’s drop puts it 303.32% from its 52-week high of EUR1.21.
Aurora Cannabis (NYSE: ACB) shares saw an alarming 12.76% drop to EUR4.24 at 10:04 EST Monday after two consecutive sessions of gains. Meanwhile, NYSE is also down 0.56% at EUR18,112.04 following yesterday’s downward trend; suggesting today may be another negative trend exchanging session.
About Aurora Cannabis
Aurora Cannabis Inc. is a leading global producer and distributor of cannabis and its derivative products. Headquartered in Edmonton, Canada, they operate three business segments: Canadian Cannabis, European Cannabis, and Plant Propagation. Aurora produces and distributes medical and consumer cannabis products throughout Canada, as well as wholesale distribution in Europe, Australia, South America and Israel. Aurora cultivates and sells various cannabis products, such as dried cannabis, oils, capsules and edibles. Aurora provides recreational products under multiple brands including Daily Special, Whistler and Being; provides patient counseling and outreach services; adult-use brands include Aurora Drift, San Rafael ’71 Greybeard Reliva and KG7; while medical brands include MedReleaf CanniMed Aurora Whistler Medical Marijuana Co Pedanios Bidiol CraftPlant
Yearly Analysis
Aurora Cannabis (ACB) currently trades at EUR4.24, significantly above its 52-week high of EUR1.21. This indicates that Aurora has experienced exceptional performance over the last year.
Aurora Cannabis currently boasts an EBITDA score of 18.09. EBITDA is calculated by adding earnings, interest, taxes, depreciation and amortization expenses together. A positive EBITDA indicates that more profit is being generated than spent on these expenses – something investors will likely take note of as they make investment decisions.
Keep in mind that the stock market can be unpredictable and past results do not guarantee future outcomes. Before making any investment decisions, investors should conduct extensive research and analysis.
Quarter Analysis
Aurora Cannabis projects sales growth of approximately 7% for its next quarter, which would follow an expected quarterly revenue increase of 84.6 and 87%, respectively, over the last 12 months. Year-on-year quarterly revenue growth stands at 30.4% and current revenues stand at 225.18M – suggesting the company is steadily expanding its revenue base and potentially providing investors with an excellent investment opportunity with strong long-term revenue projections. It should be noted however, that cannabis markets can be extremely competitive and regulated, which Aurora may face challenges keeping up its impressive revenue expansion rate.
Equity Analysis
Earnings Per Share
Aurora Cannabis currently has an Earnings Per Share ratio of EUR-58.78, indicating it is currently operating at a loss. This suggests its revenue does not cover expenses, making investing in this company unprofitable at this time.
Aurora Cannabis currently demonstrates a negative return on equity for the past 12 months – this indicates it may not be an ideal investment option right now.
Note that these financial figures are derived from historical data, so their accuracy should not necessarily predict future performance. Furthermore, cannabis markets are highly dynamic and investors must conduct extensive research prior to making investment decisions in this highly competitive industry.
More news about Aurora Cannabis (ACB).
